BMY vs GILD
Bristol Myers Squibb and Gilead Sciences, both Healthcare
Gilead Sciences is the larger company at $154B against $110B. Over the past year GILD returned +36% against +34% for BMY. The RyuScore puts BMY ahead, 54 against 44 out of 100.
| Figure | BMY | GILD |
|---|---|---|
| Last close | $59.11 | $151 |
| Market cap | $110B | $154B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 13.0 | n/a |
| Dividend yield | 4.2% | 2.1% |
| 1-year return | +34% | +36% |
| 5-year return | +14% | +155% |
| RyuScoresector-relative, 1–10 | 54/100 | 44/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 33% of the disclosed total.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.